Nicole Pfarr, Dipl.-Biol, discusses how an in-house comprehensive genomic profiling (CGP) including HRD provides fast turnaround to guide patient treatment and improves laboratory operational efficiency. Nicole Pfarr shares results of a study in pancreatic cancer, and the findings of HRD positive cases with and without BRCA mutations, and other alterations for targeted therapy. Nicole Pfarr, Dipl.-Biol, is the head of the Molecular Pathology Diagnostic Unit and of the Next Generation Sequencing Research Facility at the Technical University of Munich, Germany. Learn about CGP HRD in ovarian cancer: https://youtu.be/54yI7Sxvnfc?si=H2SeIgVR8NYpVdS2 Learn about in-house CGP and rare mutations: https://youtu.be/NErI9YCGcn4 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM LinkedIn: https://www.linkedin.com/company/illumina X: https://x.com/illumina Instagram: https://www.instagram.com/illuminainc/ Facebook: https://www.facebook.com/illuminainc TikTok: https://www.tiktok.com/@illuminainc #HRD #CGP #Illumina